Bionano Genomics (NASDAQ:BNGO) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Bionano Genomics (NASDAQ:BNGO) in a research report released on Wednesday, Marketbeat reports. The firm issued a buy rating and a $10.00 price target on the stock. HC Wainwright also issued estimates for Bionano Genomics’ Q1 2025 earnings at ($3.49) EPS, Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at ($1.87) EPS, FY2025 earnings at ($10.26) EPS, Q1 2026 earnings at ($1.60) EPS, Q2 2026 earnings at ($1.33) EPS, Q3 2026 earnings at ($1.15) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($5.12) EPS.

Separately, Scotiabank boosted their target price on Bionano Genomics from $1.00 to $4.00 and gave the company a “sector perform” rating in a research report on Wednesday, April 2nd.

Bionano Genomics Trading Up 2.7 %

NASDAQ:BNGO opened at $4.52 on Wednesday. The firm has a fifty day simple moving average of $4.10 and a two-hundred day simple moving average of $11.66. Bionano Genomics has a 12 month low of $2.68 and a 12 month high of $72.60. The stock has a market capitalization of $13.59 million, a price-to-earnings ratio of -0.03 and a beta of 2.08. The company has a current ratio of 1.43, a quick ratio of 0.99 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On Bionano Genomics

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in shares of Bionano Genomics by 47.3% in the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after buying an additional 283,639 shares in the last quarter. Carret Asset Management LLC raised its holdings in shares of Bionano Genomics by 39.9% in the 4th quarter. Carret Asset Management LLC now owns 119,000 shares of the company’s stock worth $34,000 after acquiring an additional 33,945 shares during the last quarter. Renaissance Technologies LLC bought a new position in Bionano Genomics in the 4th quarter valued at about $46,000. XTX Topco Ltd acquired a new position in Bionano Genomics during the 4th quarter valued at about $45,000. Finally, Jane Street Group LLC bought a new stake in Bionano Genomics during the 4th quarter worth approximately $118,000. 11.35% of the stock is currently owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.